Antibody composition for lymphoma immunotyping based on flow cytometry and prediction system thereof
By using antibody compositions and optimized hemolysis processes in flow cytometry, efficient lymphoma immunotyping with single-tube detection is achieved, solving the problems of low detection efficiency and difficulty in screening for cross-line antigen expression, and providing rapid, Accurate lymphoma analysis results.
Patent Information
- Application Number
- CN202411079674.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-07
- Publication Date
- 2024-11-19
- Estimated Expiration
- 2044-08-07
AI Technical Summary
Existing flow cytometry is inefficient in lymphoma immunotyping, requires multiple tests to waste antibodies, and cannot observe the link between T lymphocytes, NK lymphocytes and B lymphocytes at the same time, and cannot effectively perform cross-line antigen expression. Screening.
Provide an antibody composition based on flow cytometry, including anti-CD8, anti-CD4, anti-CD10 and other monoclonal antibodies, optimize the hemolysis process, achieve comprehensive and efficient lymphoma immunotyping through single-tube detection, and combine data analysis. Module quickly identify mixed lymphomas.
It significantly improves detection efficiency, saves antibodies, can accurately identify mixed lymphomas, provides comprehensive and efficient immunophenotypic analysis and screening suggestions, and improves work efficiency.
Smart Images

Figure CN118980822A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of medical detection, and relates to an antibody composition and a prediction system thereof for lymphoma immunophenotyping based on flow cytometry. Background Art
[0002] Flow cytometry is a detection method that can achieve quantitative analysis of single cells. It has the advantages of rapidity, high precision, and multiple parameters. It is one of the most advanced cell quantitative analysis methods. This detection method has an important impact on the test results in the hemolysis stage of preparing the test solution, especially when processing samples in batches. Due to the large number of manual operation steps, the hemolysis time is greatly affected by environmental factors. In addition, after adding hemolysin, it is necessary to incubate in the dark for about 15 minutes. The hemolysis method in the prior art takes a long time and the detection efficiency is relatively low. It is necessary to improve the hemolysis method to improve the detection efficiency.
[0003] Flow cytometry plays an important role in the diagnosis, typing, staging and monitoring of residual lesions of lymphoma. Flow cytometry immunoassay is an analysis of whether each single cell in a population of cells expresses certain specific antigens (i.e., phenotype), thereby defining the cell series (B or T / NK) and maturity (precursor cells or mature cells), providing a reliable basis for diagnosis. When performing cell phenotyping and interpreting the results, the following steps are often required: ① Determine the maturity of a certain group of cells, such as mature B cells or primitive / immature cells; ② Determine abnormal cells by distinguishing the antigen expression spectrum from normal cells; ③ Detailedly identify the phenotype of the abnormal cell population, such as the expression or absence of a certain antigen, and the increase or decrease in the fluorescence intensity of a certain antibody detection; ④ Determine whether the information of the flow cytometry test has diagnostic value; even if it does not have diagnostic value, it can provide suggestions for further examinations, such as immunohistochemistry, cytogenetics, FISH, molecular examinations, etc.; ⑤ Immunophenotyping analysis may have certain prognostic value, including identifying potential therapeutic targets. At present, most of the options in the flow cytometry industry are to detect only one antibody in each channel. However, it is often the case that some antibody channels are the same, but if you want to detect them at the same time, you need to conduct multiple tests, which not only wastes antibodies but also wastes time. In the prior art, the first-line antibodies commonly used for lymphoma typing are mostly designed as two-tube models. When analyzing, it is necessary to analyze the data of two tubes, which not only wastes some gate antibodies and reduces the experimental efficiency, but also makes it impossible to observe the connection between T lymphocytes, NK lymphocytes and B lymphocytes at the same time, and it is even more impossible to distinguish the expression of cross-lineage antigens of different lymphocytes, so that it is impossible to make targeted screening recommendations for the expression of cross-lineage antigens. Summary of the invention
[0004] In view of the above problems existing in the prior art, the first object of the present invention is to optimize the number of tubes and antibody combinations of first-line antibodies based on flow cytometry detection, and to provide an antibody composition that can comprehensively, efficiently and comprehensively perform the first step of lymphoma immunophenotyping in a single tube.
[0005] The second purpose of the present invention is to improve the hemolysis method during flow cytometry sample preparation by optimizing the incubation conditions and hemolysin types in the hemolysis process, thereby significantly improving the test solution preparation efficiency and improving the detection efficiency. In addition, in combination with the antibody composition for lymphoma immunophenotyping provided above, combined with the expression of specific antibody combinations and antibody pairs, an efficient, economical and comprehensive prediction system for lymphoma immunophenotyping based on flow cytometry is provided, which can quickly identify mixed lymphomas.
[0006] In order to achieve the above-mentioned object of the invention, the embodiment of the present invention adopts the following technical solution:
[0007] In a first aspect, the present invention provides an antibody composition for lymphoma immunophenotyping based on flow cytometry, the antibody composition comprising anti-CD8 antibody, anti-CD4 antibody, anti-CD10 antibody, anti-CD3 antibody, anti-CD56 antibody, anti-CD7 antibody, anti-CD5 antibody, anti-CD34 antibody, anti-CD10 antibody, anti-CD19 antibody, anti-CD2 antibody, anti-CD20 antibody, anti-CD45 antibody, anti-Kappa antibody and anti-Lambda antibody; the above antibodies are all monoclonal antibodies;
[0008] The antibody composition is mixed in the same flow tube during detection.
[0009] During the development of normal hematopoietic system cells, each type of cell has its own inherent antigen expression pattern, and this pattern may change in quantity or quality in tumor states such as leukemia, lymphoma and MM. Based on these changes, auxiliary diagnosis of these diseases can be performed for typing and classification. The flow cytometry detection method uses fluorescein-labeled McAbs against human cell differentiation antigens to bind to the corresponding antigens of individual cells in the sample, and uses a flow cytometer to detect the fluorescent markers bound to the cell surface, thereby analyzing the antigen expression of abnormal cell populations. Based on flow cytometry detection, the present invention optimizes the number of tubes and antibody combinations of first-line antibodies used for lymphoma immunotyping, and provides an antibody composition that only requires one tube to detect 15 antibody indicators, so as to achieve low sample requirements, rapid, comprehensive, and relatively accurate lymphoma immunotyping.
[0010] Preferably, the antibody is labeled with different fluorescent markers; the fluorescent markers are selected from FITC, PE, ECD, PE-CY7, PerCP-Cy TM5.5, APC, APC Alexa Fluor 700, Pacific Blue, Brilliant Violet 421, SparkViolet TM 538, APC-Cy7 TM 7.
[0011] Preferably, the labeling coordination relationship between the fluorescent marker and the antibody is: the labeling coordination relationship between the fluorescent marker and the antibody is: anti-Kappa antibody and anti-CD8 antibody are labeled with FTIC, anti-Lambda antibody and anti-CD4 antibody are labeled with PE, anti-CD3 antibody is labeled with ECD, and anti-CD56 antibody is labeled with PerCP-Cy TM 5.5, anti-CD7 antibody labeled with PE-Cy7, anti-CD5 antibody and anti-CD34 antibody labeled with APC, anti-CD10 antibody labeled with APC Alexa Fluor 700, anti-CD19 antibody labeled with APC-Cy7 TM 7. Anti-CD2 antibody labeled Pacific Blue, anti-CD20 antibody labeled Briliant Violet 421, anti-CD45 antibody labeled Spark Violet TM 538.
[0012] In a second aspect, the present invention provides a prediction system for lymphoma immunophenotyping based on flow cytometry, the prediction system comprising a data detection module and a data analysis module;
[0013] Wherein, the detection module is used to detect the antigen expression of the cell fluid to be tested by flow cytometry, wherein the cell fluid to be tested comprises a sample to be tested, a hemolysin composition and an antibody composition for lymphoma immunophenotyping based on flow cytometry according to any one of claims 1 to 3;
[0014] The data analysis module is used to analyze the detection results of the detection module and predict lymphoma immunophenotyping according to predetermined judgment criteria.
[0015] Preferably, the lymphoma includes B-cell lymphoma, T-cell lymphoma or NK-cell lymphoma, and a mixed lymphoma of any two of the three types of cells: B cells, T cells or NK cells.
[0016] Preferably, in the detection module, the hemolysin composition comprises OPtiLyse C reagent and FACS Lysingsolution;
[0017] The preparation process of the cell fluid to be tested includes: mixing the antibody composition for lymphoma immunophenotyping based on flow cytometry with the sample to be tested, adding OPtiLyse C reagent, incubating at 18-25° C. in the dark for 2-3 minutes, adding FACS Lysing solution, incubating at 36-38° C. in the dark for 2-3 minutes, and obtaining the cell fluid to be tested;
[0018] The sample to be tested includes a peripheral blood sample or a bone marrow sample.
[0019] Preferably, the data analysis module executes the following process: obtaining the result data of the data detection module, cutting off the adhesion and cell debris data, setting a gate with CD45-SS, and dividing the cell population into a granulocyte area, a monocyte area, a lymphocyte area, a CD45 weakly positive area and a CD45 negative area according to the expression of CD45, and after circling the target cell population, analyzing the expression of B cells, T cells, NK cells and different lymphocyte cross-lineage antigens in the lymphocyte gate.
[0020] Preferably, the analysis of the expression of B cells, T cells, NK cells and different lymphocyte cross-lineage antigens within the lymphocyte gate specifically includes the following contents:
[0021] (1) Analysis of B cells within the lymphocyte gate, including gating B cells using CD19-SS;
[0022] Observe the CD45 weakly positive area or CD45 negative area, and combine the expression of CD34 and CD20-CD10 pattern to predict the probability of B lymphoblastic leukemia;
[0023] Observe the development trend of B progenitor cells and mature B cells, and predict the probability of B cell lymphoma based on the proportion of mature B cells in lymphocytes;
[0024] Observe the expression of Kappa-Lambda light chain on the membrane of mature B cells to predict the probability of B-cell lymphoma;
[0025] (2) Analysis of T cells and NK cells within the lymphocyte gate, including gating T cells and NK cells using CD3-SS;
[0026] Observe the CD45 weakly positive area or CD45 negative area, and combine it with the expression of CD34 to predict the probability of T lymphoblastic leukemia;
[0027] Observe the CD4 / CD8 ratio in T cells within the logical lymphatic gate, whether the pan-T cell antigen expression is abnormal, or whether there is abnormal increase in the expression of a single antigen in T cells, and predict the probability of T cell lymphoma;
[0028] Observe the NK cells in the lymphocyte gate, including circling NK cells or T cells with CD3-CD19-, observe the ratio of NK cells to lymphocytes in the logical lymphocyte gate, and predict the probability of NK cell lymphoma by combining the abnormal expression of antigens including CD56, CD7, CD2 or CD5;
[0029] (3) Based on the above analysis results of the expression of B cells, T cells, NK cells and cross-lineage antigens in the lymphocyte gate, the probability of mixed lymphoma of any two of the three types of cells, B cells, T cells or NK cells, is predicted.
[0030] Preferably, in the analysis of B cells in the lymphocyte gate, when the ratio of Kappa / Lambda of the cell membrane light chain of the mature B cells does not fall within the range of 0.3 to 3.0 or Kappa / Lambda is not expressed, the cells are determined to be abnormal mature B cells, and the probability of B cell lymphoma is predicted based on the ratio of the abnormal mature B cells;
[0031] Further, according to the expression of CD5 and CD10, the prediction result is output as follows: suspected CD5 + CD10 - B-cell lymphoma, CD5 - CD10 - B-cell lymphoma, CD5 + CD10 + B-cell lymphoma or CD5 - CD10 + Any type of B-cell lymphoma;
[0032] The analysis of T cells and NK cells in the lymphocyte gate, when the proportion of T cells in the logical lymphocyte gate to lymphocytes is greater than 70% or when the CD4 / CD8 ratio of T cells in the logical lymphocyte gate does not fall within the range of 0.5 to 3.0, predicts the probability of T cell lymphoma;
[0033] The analysis of T cells and NK cells in the lymphocyte gate, CD3-CD19- gate, CD4+ accompanied by abnormal expression of CD56, CD5, CD7 or CD2 antigens is determined to be abnormal T cells, and the probability of T cell lymphoma is predicted based on the proportion of the abnormal T cells;
[0034] The T cells and NK cells in the lymphocyte gate are analyzed. When the proportion of NK cells in the logical lymphocyte gate to lymphocytes is greater than 40%, or CD4- in the CD3-CD19- gate is accompanied by abnormal expression of CD56, CD5, CD7 or CD2 antigens, the probability of T cell lymphoma or NK cell lymphoma is predicted.
[0035] Preferably, the analysis of the expression of cross-lineage antigens of different lymphocytes by lymphocytes is performed by analyzing the expression of specific antibody pairs or antibodies within the logical lymphatic gate, observing the cross-lineage expression between different lymphocytes, and outputting the prediction results of targeted subsequent screening;
[0036] The specific antibody pairs or antibody combinations include (CD5+CD34)-CD10, CD3-CD10, CD7-CD10 or CD3-CD19 or CD19-CD7 or CD19-CD56.
[0037] Compared with the prior art, the present invention has the following beneficial effects:
[0038] The present invention comprehensively considers the mechanisms or specific lymphoma characteristics including the following seven factors, and provides an antibody composition for primary screening of lymphoma immunophenotyping, wherein the seven factors are as follows: a). Normal T lymphocytes express CD3, CD5, CD2, CD7, but do not express Kappa, Lambda, CD20, CD19; b). Normal NK lymphocytes express CD7, CD2, CD56, but do not express CD3, Kappa, Lambda, CD20, CD19; c). Normal B lymphocytes express Kappa, Lambda, CD20, but do not express CD3, CD7, CD2; d). Normal lymphocytes at all maturation stages do not express CD34; e). Combinations of CD8 and Kappa, CD4 and Lambda, CD5 and CD34, CD2 and CD20 have the same fluorescent channel after corresponding fluorescent labeling; f). Abnormal expression of certain antibodies, antibody pairs or antibody combinations in specific lymphomas; g). By observing the expression of (CD5+CD34)-CD10 / CD3-CD10 / CD7-CD10 / CD3-CD19 / CD19-CD7 / CD19-CD56 and other expressions in the logical lymphatic gate, cross-lineage expression between different lymphocytes can be identified. In view of the fact that the antibody composition designed by the present invention for lymphoma immunophenotyping is more comprehensively considered, various antibody indicators can be reasonably applied, covering a wide range, and can accurately identify mixed lymphomas and analyze their immunophenotypes, combining multiple judgment factors to facilitate rapid result judgment, and make more comprehensive and targeted suggestions for subsequent screening.
[0039] The present invention improves the traditional flow sample preparation method by appropriately increasing the incubation temperature after adding a certain hemolysin and optimizing the type of hemolysin, shortening the incubation time after adding the hemolysin from 15 minutes in the traditional hemolysis process to 4 to 6 minutes, which can significantly improve the detection efficiency.
[0040] Through the methodological verification of the improved flow sample preparation method and the analysis method of lymphoma using the antibody composition for lymphoma immunophenotyping provided by the present invention, it can be seen that the accuracy and precision of the improved flow sample preparation method and analysis method are better than the traditional flow sample preparation method / traditional two-tube analysis method. The prediction method for lymphoma immunophenotyping provided by the present invention can greatly shorten the experimental time, save antibodies, improve work efficiency, and provide a comprehensive, efficient and comprehensive prediction conclusion of lymphoma immunophenotyping. In particular, it can quickly identify mixed lymphoma. BRIEF DESCRIPTION OF THE DRAWINGS
[0041] In order to more clearly illustrate the technical solutions in the embodiments of the present invention, the drawings required for use in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.
[0042] Figure 1 The cell to be tested in Example 2 of the present invention is cut off from the adhesion bodies and cell fragments and its CD45-SS detection diagram is as follows Figure 1 As shown, Figure 1 a) is the detection picture after the adhesion of the cells to be tested is cut off; Figure 1 b) is a detection picture after cutting off adhesion bodies and cell fragments; Figure 1 c) The cells to be tested are CD45-SS detection images;
[0043] Figure 2 This is a detection diagram of B cell development and lymphocyte proportion in Example 2 of the present invention, wherein Figure 2 a) is a detection diagram of CD19 positive cells to be tested; Figure 2 b) is a detection diagram of CD10 and CD20 developmental patterns of B progenitor cells and B cells; Figure 2 c) Detection chart of the ratio of B cells to lymphocytes;
[0044] Figure 3 This is a detection diagram of the B cell immunophenotype (expression of CD5, CD20, CD10 or cell membrane light chains Kappa and Lambda) in Example 2 of the present invention, wherein Figure 3 a) is a detection diagram of the expression of CD5 in B cells to be tested; Figure 3 b) is a detection diagram of the expression of CD20 on B cells; Figure 3 c) is the expression of CD10 on B cells; Figure 3 d) is a detection diagram of the expression of Kappa and Lambda light chains on the B cell membrane;
[0045] Figure 4This is a detection diagram of the proportion of T cells and NK cells in lymphocytes in Example 2 of the present invention, wherein Figure 4 a) is a CD3 positive cell detection diagram; Figure 4 b) is a detection diagram of the proportion of CD3 positive cells to lymphocytes; Figure 4 c) Detection chart of CD3 positive T cells, NKT cells, and the proportion of NK cells in lymphocytes;
[0046] Figure 5 This is a graph showing the development of CD4 and CD8 in T cells in Example 2 of the present invention, wherein Figure 5 a) is a detection diagram of T cell CD4 expression; Figure 5 b) is a detection diagram of T cell CD8 expression; Figure 5 c) is a detection diagram of CD4+CD8+T cells, CD4+CD8-T cells, CD4-CD8+T cells, and the proportion of CD4-CD8+T cells in T cells;
[0047] Figure 6 This is a graph showing the development of CD7, CD5 and CD2 in T cells and NK cells in Example 2 of the present invention, wherein Figure 6 a) is a graph showing the detection of CD7 expression in T cells and NK cells; Figure 6 b) is a graph showing the detection of CD5 expression in T cells and NK cells; Figure 6 c) is a graph showing the detection of CD2 expression in T cells and NK cells;
[0048] Figure 7 This is a detection diagram for observing whether different lymphocytes express across lines in Example 2 of the present invention, wherein Figure 7 a) is the lymphocyte CD3 / CD19 detection diagram; Figure 7 b) is the detection diagram of lymphocyte CD3 / CD10 expression; Figure 7 c) is the detection diagram of lymphocyte CD7 / CD10 expression; Figure 7 d) is the detection diagram of lymphocyte CD56 / CD19 expression;
[0049] Figure 8 This is a typical case of the target object 1 in the present invention, after the adhesion and cell fragments are cut off from the cells to be tested and the CD45-SS detection diagram, wherein Figure 8 a) is the detection picture after the adhesion of the cells to be tested is cut off; Figure 8 b) is a detection picture after cutting off adhesion bodies and cell fragments; Figure 8 c) is a CD45-SS detection diagram of cells to be tested;
[0050] Fig. 9 This is a detection diagram of B cell development and lymphocyte ratio in target object 1 in a typical case of the present invention, wherein Fig. 9 a) is a detection diagram of CD19 positive cells to be tested; Fig. 9 b) is a detection diagram of CD10 and CD20 developmental patterns of B progenitor cells and B cells; Fig. 9 c) Detection chart of the ratio of B cells to lymphocytes;
[0051] Fig.10 This is a detection diagram of B cell immune phenotype (expression of CD5, CD10 or cell membrane light chain Kappa and Lambda) in target object 1 in a typical case of the present invention; wherein Fig.10 a) is a detection diagram of the expression of CD5 in B cells to be tested; Fig.10 b) is the expression of CD10 on the B cells to be tested; Fig.10 c) is a detection diagram of the expression of Kappa and Lambda light chains on the cell membrane of the B cells to be tested;
[0052] Fig.11 This is a detection diagram of the proportion of T cells and NK cells to lymphocytes in target object 1 in a typical case of the present invention; Fig.11 a) is a CD3 positive cell detection diagram; Fig.11 b) is a detection diagram of the proportion of CD3 positive cells to lymphocytes; Fig.11 c) Detection chart of CD3 positive T cells, NKT cells and the proportion of NK cells in lymphocytes;
[0053] Fig.12 This is a detection diagram of CD4 and CD8 development in T cells in target object 1 in a typical case of the present invention; wherein Fig.12 a) is a detection diagram of T cell CD4 expression; Fig.12 b) is a detection diagram of T cell CD8 expression; Fig.12 c) is a detection diagram of CD4+CD8+T cells, CD4+CD8-T cells, CD4-CD8+T cells and the proportion of CD4-CD8+T cells to T cells;
[0054] Fig.13 This is a detection diagram of the development of CD7, CD5 and CD2 in T cells and NK cells in target object 1 in a typical case of the present invention; wherein Fig.13 a) is a detection diagram of CD7 expression in T cells and NK cells; Fig.13 b) is a detection diagram of CD5 expression in T cells and NK cells; Figure c) is a detection diagram of CD2 expression in T cells and NK cells;
[0055] Fig.14 This is a detection diagram of whether different lymphocytes express across lineages in target object 1 in a typical case of the present invention; Fig.14 a) is the lymphocyte CD3 / CD19 detection diagram; Fig.14 b) is the detection diagram of lymphocyte CD3 / CD10 expression; Fig.14c) is the detection diagram of lymphocyte CD7 / CD10 expression; Fig.14 d) is the detection diagram of lymphocyte CD56 / CD19 expression;
[0056] Fig.15 This is a detection diagram of the proportion of T cells and NK cells in lymphocytes in target object 2 in a typical case of the present invention, where Fig.15 a) is a CD3 positive cell detection diagram; Fig.15 b) is a detection diagram of the proportion of CD3 positive cells to lymphocytes; Fig.15 c) Detection chart of CD3 positive T cells, NKT cells, and the proportion of NK cells in lymphocytes;
[0057] Fig.16 This is a T cell CD4 and CD8 development detection diagram in target object 2 in a typical case of the present invention; wherein Fig.16 a) is a detection diagram of T cell CD4 expression; Fig.16 b) is a detection diagram of T cell CD8 expression; Fig.16 c) is a detection diagram of the proportion of T cells CD4+CD8+T cells, CD4+CD8-T cells, CD4-CD8+T cells, and CD4-CD8+T cells to T cells;
[0058] Fig.17 This is a development detection diagram of CD7, CD5, and CD2 of T cells and NK cells in target object 2 in a typical case of the present invention; Fig.17 a) is a detection diagram of CD7 expression in T cells and NK cells; Fig.17 b) is the detection diagram of CD5 expression of T cells and NK cells; Fig.17 c)
[0059] This is the detection diagram of CD2 expression in T cells and NK cells;
[0060] Fig.18 This is a detection diagram of B cell development and lymphocyte proportion in target object 3 in a typical case of the present invention; wherein Fig.18 a) is a detection diagram of CD19 positive cells to be tested; Fig.18 b) is a detection diagram of CD10 and CD20 developmental patterns of B progenitor cells and B cells; Fig.18 c) Detection chart of the ratio of B cells to lymphocytes;
[0061] Fig.19 This is a detection diagram of the B cell immune phenotype and the development of CD7, CD5 and CD2 of T cells and NK cells in target object 3 in a typical case of the present invention; wherein Fig.19 a) is a detection diagram of the expression of CD5 in B cells to be tested; Fig.19 b) is the expression of CD10 on the B cells to be tested; Fig.19c) is a detection diagram of the expression of Kappa and Lambda light chains on the cell membrane of the B cells to be tested; Fig.19 d) is the detection diagram of CD7 expression in T cells and NK cells; Fig.19 e) is a detection diagram of CD5 expression in T cells and NK cells; Fig.19 f) is a detection diagram of CD2 expression in T cells and NK cells;
[0062] Fig. 20 This is a detection diagram of the proportion of T cells and NK cells in lymphocytes in target object 3 in a typical case of the present invention; Fig. 20 a) is a CD3 positive cell detection diagram; Fig. 20 b) is a detection diagram of the proportion of CD3 positive cells to lymphocytes; Fig. 20 c) Detection chart of CD3 positive T cells, NKT cells and the proportion of NK cells in lymphocytes;
[0063] Fig.21 This is a CD45-SS detection diagram of the cells to be tested in tube 1 of comparative example 1 of the present invention after the adhesion bodies and cell fragments are cut off, wherein Fig.21 a) is the detection picture after the adhesion of the cells to be tested is cut off; Fig.21 b) is a detection picture after cutting off adhesion bodies and cell fragments; Fig.21 c) is a CD45-SS detection diagram of cells to be tested;
[0064] Fig. 22 This is a detection diagram of the ratio of T cells and NK cells to lymphocytes in tube 1 of comparative example 1 of the present invention, wherein Fig. 22 a) is a CD3 positive cell detection diagram; Fig. 22 b) is a detection diagram of the proportion of CD3 positive cells to lymphocytes; Fig. 22 c) Detection chart of CD3 positive T cells, NKT cells, and the proportion of NK cells in lymphocytes;
[0065] Fig.23 This is a graph showing the development of CD4 and CD8 T cells in tube 1 of comparative example 1 of the present invention, wherein Fig.23 a) is a detection diagram of T cell CD4 expression; Fig.23 b) is a detection diagram of T cell CD8 expression; Fig.23 c) is a detection diagram of the proportion of CD4+CD8+T cells, CD4+CD8-T cells, CD4-CD8+T cells and CD4-CD8+T cells in T cells;
[0066] Fig.24 This is a graph showing the development of CD7, CD5, and CD2 of T cells and NK cells in tube 1 of comparative example 1 of the present invention, wherein Fig.24 a) is a detection diagram of CD7 expression in T cells and NK cells; Fig.24b) is the detection diagram of CD5 expression of T cells and NK cells; Fig.24 c) is a detection diagram of CD2 expression in T cells and NK cells;
[0067] Fig.25 This is a detection diagram of the development of B cells and the proportion of lymphocytes in the cells to be tested in tube 2 of comparative example 1 of the present invention, wherein Fig.25 a) is a detection diagram of CD19 positive cells to be tested; Fig.25 b) is a detection diagram of CD10 and CD20 developmental patterns of B progenitor cells and B cells; Fig.25 c) is a detection diagram of the proportion of B cells to lymphocytes;
[0068] Fig.26 The detection diagram of B cell immunophenotype (expression of CD5, CD20, CD10 and cell membrane light chains Kappa and Lambda) in the test cells in tube 2 of comparative example 1 of the present invention is as follows Fig.26 As shown, Fig.26 a) is a detection diagram of the expression of CD5 in B cells to be tested; Fig.26 b) is a detection diagram of the expression of CD20 on B cells; Fig.26 c) is the expression of CD10 on B cells; Fig.26 d) is the detection diagram of the expression of B cell membrane light chains Kappa and Lambda. DETAILED DESCRIPTION
[0069] In order to make the purpose, technical solution and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with the embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not used to limit the present invention.
[0070] Unless otherwise specified, the experimental methods used in the following examples are conventional methods.
[0071] All materials and reagents in the following examples, unless otherwise specified, can be obtained from commercial sources.
[0072] The instruments used in the present invention include: Navios flow cytometer, purchased from Beckman Coulter, USA, and KUALZA software was used to analyze the data;
[0073] The reagents used in the present invention include: anti-CD8 antibody, anti-CD4 antibody, anti-CD10 antibody, anti-CD3 antibody, anti-CD56 antibody, anti-CD7 antibody, anti-CD5 antibody, anti-CD34 antibody, anti-CD10 antibody, anti-CD19 antibody, anti-CD2 antibody, anti-CD20 antibody, anti-CD45 antibody, anti-Kappa antibody and anti-Lambda antibody are all purchased from Beckman Coulter, Becton, Dickinson and Company, Biolegend and Henan Kaiprei Company;
[0074] Optilysec hemolysin was purchased from Beckman Coulter, USA;
[0075] BD FACS Lysing solution was purchased from Becton, Dickinson and Company;
[0076] The washing solution in the present invention is a PBS buffer solution (pH 7.0-7.4) containing 1% calf serum.
[0077] The present invention uses flow cytometry to determine the series and differentiation stage of lymphoma cells in bone marrow samples or peripheral blood samples of clinical patients, and can be used for the initial screening of lymphoma immunophenotyping. In the embodiments of the present invention, bone marrow samples are used as an example for explanation, and the same processing and analysis can also be performed on peripheral blood samples, and further prediction of lymphoma immunophenotyping can be made based on the analysis results.
[0078] When analyzing data, the present invention calculates the positive ratio of antigen expression for each group of cells with negative and positive expression of antigens. When <20%, it is defined as negative (-) or described as no expression; ≥20% is defined as positive (+).
[0079] x% of the predicted results are subject to the actual test results.
[0080] Example 1 An antibody composition for lymphoma immunophenotyping based on flow cytometry
[0081] This embodiment provides an antibody composition for lymphoma immunophenotyping based on flow cytometry: the antibody composition consists of anti-CD8 antibody, anti-CD4 antibody, anti-CD10 antibody, anti-CD3 antibody, anti-CD56 antibody, anti-CD7 antibody, anti-CD5 antibody, anti-CD34 antibody, anti-CD10 antibody, anti-CD19 antibody, anti-CD2 antibody, anti-CD20 antibody, anti-CD45 antibody, anti-Kappa antibody and anti-Lambda antibody; the above antibodies are all monoclonal antibodies.
[0082] After opening the bottles of different antibodies, titer verification experiments were carried out, and the most suitable amount was taken for the experiment.
[0083] The above antibodies can be labeled with corresponding fluorescein according to the common knowledge of those skilled in the art. This embodiment is described by taking the antibodies, dosages and corresponding fluorescein labels in Table 1 below as an example.
[0084] Table 1
[0085] Antibody name / dosage Fluorescein labeling Anti-Kappa antibody (2.5 μL) + anti-CD8 antibody (5 μL) FITC Anti-Lambda antibody (2.5 μL) + anti-CD4 antibody (5 μL) PE Anti-CD3 antibody (5 μL) ECD Anti-CD56 antibody (2.5 μL) <![CDATA[PerCP-Cy TM 5.5]]> Anti-CD7 antibody (2.5 μL) PE-CY7 Anti-CD5 antibody (1.25 μL) + anti-CD34 antibody (1.25 μL) APC Anti-CD10 antibody (1.25 μL) APC Alexa Fluor 700 Anti-CD19 antibody (2.5 μL) <![CDATA[APC-Cy7 TM 7]]> Anti-CD2 antibody (1.25 μL) + anti-CD20 antibody (1.25 μL) Pacific Blue and Briliant Violet 421 Anti-CD45 antibody (1.25 μL) <![CDATA[Spark Violet TM 538]]>
[0086] Example 2 A prediction system for lymphoma immunophenotyping based on flow cytometry
[0087] This embodiment provides a prediction system for lymphoma immunophenotyping based on flow cytometry, and the prediction system includes a data detection module and a data analysis module.
[0088] The detection module includes detecting the antigen expression of the cell fluid to be tested by flow cytometry, wherein the preparation of the cell fluid to be tested includes mixing the antibody composition and the hemolysin composition described in Example 1 with the bone marrow sample to be tested to prepare the cell fluid to be tested;
[0089] The data analysis module is used to analyze the detection results of the detection module and predict lymphoma immunophenotyping according to predetermined judgment criteria.
[0090] 1. The detection module includes the preparation of the cell fluid to be tested and the on-machine detection. The specific operation process is as follows:
[0091] (1) Take 2 mL of human bone marrow sample and immediately place it in a heparin anticoagulant tube and mix well to prevent the sample from coagulating to obtain the test sample;
[0092] (2) Cell counting: Take 10 μL of the above sample and add 150 μL of PBS, mix well, and count the number of cells per microliter. According to the test results, the number of cells in each tube is controlled at 1×10 6 ~2×10 6 indivual;
[0093] (3) Add the antibody composition in Table 1 of Example 1 and 100 μL of the cell solution adjusted for cell concentration in step (2) to each test tube, gently rotate the test tube, and incubate at room temperature (18° C. to 25° C.) for 15 min under the conditions specified in the antibody data sheet;
[0094] (4) Add 0.5 mL of OPtiLyse C reagent and vortex immediately, incubate at room temperature (18°C-25°C) in the dark for 2.5 min; dilute FACS Lysing solution (10X) with distilled water to make FACS Lysing solution (1×), add 2 mL of room temperature FACS Lysing solution (1×) to each tube, mix immediately at low speed, and incubate in a 37°C water bath in the dark for 2.5 min;
[0095] (5) Centrifuge at 300 g for 5 min at room temperature;
[0096] (6) Discard the supernatant and leave about 50uL of liquid in the test tube to avoid damaging the cell pellet;
[0097] (7) Mix at low speed, resuspend the cells in PBS buffer containing 1% calf serum, add 2 mL of PBS containing 0.1% sodium azide to each tube to wash the cells, mix at low speed, and centrifuge at 300 g for 5 min at room temperature;
[0098] (8) Aspirate the supernatant, leaving about 50uL of liquid in the test tube to avoid damaging the cell cluster; mix at low speed, resuspend the cells in PBS buffer containing 1% calf serum, add 500uL PBS to each tube, and mix at low speed.
[0099] (10) Cover the processed sample tube and obtain the cell fluid to be tested. Store the cell fluid in the dark at 2-8°C until it is ready for testing. It is best to analyze the sample within 24 hours after staining. Mix the suspension thoroughly before loading to prevent cell aggregation.
[0100] (11) Turn on the Navios flow cytometer and preheat the machine for more than 20 minutes. Test the internal quality control product to ensure that all test values are within the control range. Load the AL-PANEL sample and collect data. According to the set instrument conditions, obtain 300,000 cells per tube.
[0101] 2. The data analysis module is used to analyze the detection results of the detection module and predict lymphoma immunophenotyping according to the predetermined judgment criteria. Specifically, it includes using KUALZA software to analyze data, setting gates for analysis and outputting prediction results in the following manner. The specific contents are as follows:
[0102] S1. Establishment of CD45-SS map
[0103] Select the live single cell gate, cut off the adhesions through the combination of FS INT and FS PEAK, cut off the cell fragments through CD45-FS, and establish the CD45-SS graph. The cell population after cutting off the cell fragments is roughly divided into five gates: Granulocyte, Monocytes, Lymphocytes, CD45dim, and CD45neg. In normal bone marrow, lymphocytes account for 20-40%, monocytes 2-8%, granulocytes 40-60%, nucleated red blood cells 2-15%, and immature cells less than 5%. Among them, the cells to be tested after cutting off the adhesions and cell fragments and their CD45-SS detection graph are shown in the figure below. Figure 1 As shown, Figure 1 a) is the detection picture after the adhesion of the cells to be tested is cut off; Figure 1 b) is a detection picture after cutting off adhesion bodies and cell fragments; Figure 1 c) The cells to be tested are CD45-SS detection diagram.
[0104] S2. Analysis of B cells within the lymphocyte gate
[0105] The CD19-SS gate was used to circle out the CD19+ B cells with CD3-CD7-. The lymphoid B cell gate included B lymphocytes, B progenitor cells, and plasma cells.
[0106] (1) In the CD45dim or CD45neg gate, if CD34 is positive and the CD20-CD10 pattern is abnormal, it is judged as abnormal primitive / immature B cells. When the proportion of abnormal primitive / immature B cells in B cells is greater than 20%, the output prediction result is: suspected B lymphoblastic leukemia; when the proportion of abnormal primitive / immature B cells is less than or equal to 20%, the output prediction result is: visible x% abnormal primitive / immature B cells. The x% is subject to the actual test results, the same below.
[0107] (2) Observe the development trend of B progenitor cells and mature B cells. Observe the proportion of mature B cells in lymphocytes (CD19 + CD20 + The proportion of B lymphocytes in normal lymphocytes is 10-20%. If the development trend of B progenitor cells and mature B cells is abnormal and the proportion of mature B cells in lymphocytes is higher than 20%, the prediction system outputs the result: suspected B cell lymphoma.
[0108] Through the logical lymphocyte gate, the expression of CD5, CD10, CD20 or CD34 of B lymphocytes is observed. In normal lymphocytes, mature B cells express CD20 and CD19, a small amount of CD5, and no CD34 and CD10. If it is observed that the expression of CD5 is enhanced, the expression of CD10 is abnormal, the expression of CD20 is enhanced, or the expression of CD20 is weakened; and the proportion of abnormal B cells is greater than 20%, the prediction system outputs the result: suspected B cell lymphoma.
[0109] Among them, the detection chart of B cell development and lymphocyte proportion is as follows Figure 2 As shown, where: Figure 2 a) is a detection diagram of CD19 positive cells to be tested; Figure 2 b) is a detection diagram of CD10 and CD20 developmental patterns of B progenitor cells and B cells; Figure 2 c) Detection chart of the ratio of B cells to lymphocytes.
[0110] (3) Through the logical B cell gate, observe the expression of Kappa-Lambda, the membrane light chain of mature B cells. The Kappa:Lambda ratio of normal B cell membrane light chain expression is 0.3-3. If the Kappa:Lambda ratio of B cell membrane light chain expression does not fall within the range of (0.3, 3) or Kappa and Lambda are not expressed, it is judged as an abnormal mature B cell. If the proportion of abnormal mature B cells in B cells is greater than 20%, the output prediction result is: suspected B cell lymphoma; if the proportion of abnormal mature B cells in B cells is less than or equal to 20%, the output prediction result is: x% abnormal mature B cells are visible.
[0111] If the prediction result is suspected B-cell lymphoma, CD5+10-B-cell lymphoma, CD5+CD10+B-cell lymphoma, CD5-CD10-B-cell lymphoma and CD5-CD10+B-cell lymphoma can be further preliminarily screened out according to the expression of CD5 and CD10; the output prediction result is CD5+CD10- B-cell lymphoma, CD5-CD10- B-cell lymphoma, CD5+CD10+ B-cell lymphoma or CD5-CD10+ B-cell lymphoma, and the corresponding prediction result is output.
[0112] Among them, the B cell immune phenotype (CD5, CD20, CD10 or cell membrane light chain Kappa and Lambda expression) detection chart is as follows Figure 3 As shown, Figure 3 a) is a detection diagram of the expression of CD5 in B cells to be tested; Figure 3 b) is a detection diagram of the expression of CD20 on B cells;
[0113] Figure 3c) is the expression of CD10 on B cells; Figure 3 d) is the detection diagram of the expression of B cell membrane light chains Kappa and Lambda.
[0114] S3. Analysis of T cells and NK cells within the lymphocyte gate
[0115] Normal T cells account for 50-70%, NKT cells account for 20-30%, and NK cells account for 10-40%. T-cell lymphoma and NK-cell lymphoma will have an increase in the corresponding lymphocyte ratio.
[0116] Through the logical lymphatic gate, observe the CD3 / CD56 graph, where CD3+CD19- is T cells, CD3+CD56+ is NKT cellsNKT, CD3-CD56+ is NK cells, CD3-CD19- is NK cells or abnormal T cells, display the proportion of cells in the gate, and observe lymphatic T cells and NK cells. The details are as follows:
[0117] (1) Observe the proportion of T cells to lymphocytes in the lymphocyte gate through the logical lymphocyte gate CD3+CD19-.
[0118] If CD45dim or CD45 is negative and CD34+, it is determined to be abnormal primitive / immature T cells. When the proportion of abnormal primitive / immature T cells is greater than 20%, the output prediction result is: suspected acute T lymphocytic leukemia; when the proportion of abnormal primitive / immature T cells is less than or equal to 20%, the output prediction result is: x% abnormal primitive / immature T cells are visible;
[0119] If CD45+CD34-, it is determined to be a T cell. According to the CD4 / CD8 ratio, the proportion of CD4+CD8+ in T cells, the proportion of CD4-CD8- in T cells, whether the pan-T cell antigen expression is abnormal, or whether there is an abnormal increase in the expression of a single antigen in T cells, it is determined whether it is an abnormal T cell. When the proportion of abnormal T cells is greater than 20%, the output prediction result is: suspected T cell lymphoma; when the proportion of abnormal T cells is less than or equal to 20%, the output prediction result is: x% abnormal T cells are visible.
[0120] Among them, if the expression of CD4-CD8 in T lymphocytes is observed, such as the ratio of CD4 to CD8 in T cells, the CD4 / CD8 ratio of normal T cells is obviously unbalanced, such as CD4 / CD8 ratio greater than 10:1 or less than 1:10, it is judged as abnormal T cells. If the proportion of such abnormal T cells is greater than 20%, the output prediction result is: suspected T cell lymphoma.
[0121] If CD5, CD7 or CD2 antigens are expressed abnormally (such as missing, enhanced or weakened) compared with normal cells, such as abnormal increase in CD10 antigen expression, it is judged as abnormal T cells. If the proportion of such abnormal T cells is greater than 20%, the predicted result is: suspected T cell lymphoma.
[0122] It is important to observe the CD4 / CD8 ratio. If the CD4 / CD8 ratio is unbalanced, greater than 10:1 or less than 1:10, a large number of CD8+T cells can be seen during viral infection accompanied by downregulation of CD7 expression, so pay attention to identification;
[0123] Among the abnormal pan-T cell antigen expression, abnormal expression of CD3, CD5, and CD7 is more common, while abnormal expression of CD2 is relatively rare. Antigen expression is often reduced or absent, and a small number of patients may show upregulated antigen expression;
[0124] The expression of certain antigens in T cells is abnormally elevated, such as CD10.
[0125] (2) Observe the CD3-CD19-Logic Gate
[0126] If CD56+, further combined with whether the antigen expression including CD7, CD2 or CD5 is abnormal, the probability of NK cell lymphoma is predicted;
[0127] If CD4+ is accompanied by abnormal expression of CD56, CD5, CD7 or CD2 antigens or abnormally elevated expression of certain antigens (such as CD10), it is determined to be abnormal T cells. When the proportion of abnormal T cells is greater than 20%, the output prediction result is: suspected T-cell lymphoma; when the proportion of abnormal T cells is less than or equal to 20%, the output prediction result is: x% abnormal T cells are visible.
[0128] If CD4- is accompanied by abnormal expression of CD56, CD5, CD7 or CD2 antigens, it is judged as abnormal T cells or abnormal NK cells. When the proportion of abnormal T cells or abnormal NK cells is greater than 20%, the output prediction result is: suspected T cell type or NK cell type lymphoma; when the proportion of abnormal T cells or abnormal NK cells is less than or equal to 20%, the output prediction result is: x% abnormal T cells or NK cells are visible.
[0129] Among them, the proportion of T cells and NK cells in lymphocytes is shown in the figure below. Figure 4 As shown, Figure 4 a) is a CD3 positive cell detection diagram; Figure 4 b) is a detection diagram of the proportion of CD3 positive cells to lymphocytes; Figure 4 c) Detection chart of CD3 positive T cells, NKT cells, and the proportion of NK cells in lymphocytes.
[0130] Figure 2. CD4 and CD8 development detection in T cells Figure 5 As shown, Figure 5 a) is a detection diagram of T cell CD4 expression; Figure 5 b) is a detection diagram of T cell CD8 expression; Figure 5 c) is a detection diagram of CD4+CD8+T cells, CD4+CD8-T cells, CD4-CD8+T cells, and the proportion of CD4-CD8+T cells in T cells;
[0131] The development detection of CD7, CD5 and CD2 in T cells and NK cells is shown in the figure Figure 6 As shown, Figure 6 a) is a graph showing the detection of CD7 expression in T cells and NK cells; Figure 6 b) is a graph showing the detection of CD5 expression in T cells and NK cells; Figure 6 c) is the detection diagram of CD2 expression in T cells and NK cells.
[0132] S4. Analysis of the expression of different lymphocyte cross-lineage antigens in lymphocytes
[0133] Logical lymphatic gate, through the expression of antigens such as (CD5+CD34)-CD10 / CD3-CD10 / CD7-CD10 / CD3-CD19 / CD19-CD7 / CD19-CD56, observe the cross-lineage expression between different lymphocytes. The flow analysis method provided by the present invention can more clearly find the cross-lineage expression of abnormal cells, making the subsequent screening more targeted. For example: abnormal T cells lose membrane CD3 / CD3 expression weakened, and express CD10 at the same time, the output prediction result is: suspected angioimmunoblastic lymphoma, it is recommended to combine bone marrow biopsy and IHC examination for further screening; if abnormal B cells express CD7, the output prediction result is: suspected B cell lymphoma combined with T cell lymphoma, it is recommended to combine second-line antibody cCD3 for further screening; if abnormal T cells express CD19, the output prediction result is: suspected T cell lymphoma accompanied by B cell lymphoma, it is recommended to combine second-line antibodies cCD79a and CD22 for further screening.
[0134] Observe whether different lymphocytes express across lines. Figure 7 As shown, Figure 7 a) is the lymphocyte CD3 / CD19 detection diagram; Figure 7 b) is the detection diagram of lymphocyte CD3 / CD10 expression; Figure 7 c) is the detection diagram of lymphocyte CD7 / CD10 expression; Figure 7 d) is the detection diagram of lymphocyte CD56 / CD19 expression.
[0135] S5. Based on the above analysis results of the expression of B cells, T cells or NK cells and cross-lineage antigens in the lymphocyte gate, predict whether it is a mixed lymphoma of any two of the three types of cells: B cells, T cells or NK cells.
[0136] The prediction system for lymphoma immunophenotyping based on flow cytometry provided in this embodiment has the following advantages:
[0137] (1) The present invention improves the traditional flow cytometry sample preparation method by adding two hemolysins and improving the incubation temperature, shortening the incubation time after adding the hemolysins from 15 minutes in the traditional hemolysis process to 4.5 minutes, which can significantly reduce the flow cytometry sample preparation time and significantly improve the detection efficiency;
[0138] (2) The single-tube combination can simultaneously observe T lymphocytes, B lymphocytes, and NK lymphocytes, avoiding duplication of gate antibodies, saving reagents, and improving work efficiency;
[0139] (3) It is more advantageous for observing certain mixed lymphomas and can quickly identify different clonal proliferation populations in the same patient, such as patients with both clonal proliferation of mature T lymphocytes and clonal proliferation of mature B lymphocytes;
[0140] (4) It can quickly identify different stages of clonal proliferation populations in the same patient, such as patients with both clonal proliferation of mature T lymphocytes and clonal proliferation of primitive B lymphocytes, patients with both clonal proliferation of mature B lymphocytes and clonal proliferation of primitive T lymphocytes, and the discovery of some other primitive stage cells that do not express T and B lineages.
[0141] Example 3 A prediction system for lymphoma immunophenotyping based on flow cytometry
[0142] This embodiment provides a prediction system for lymphoma immunophenotyping based on flow cytometry, which is basically the same as the prediction system provided in Example 2, except that: the detection module includes a preparation process of the cell fluid to be tested, after adding the OPtiLyse C reagent, incubating at room temperature (18°C to 25°C) in the dark for 2.0 min; after adding 2 mL of room temperature FACS Lysing solution (1×), incubating in a 37°C water bath in the dark for 2.0 min, and the remaining steps and parameters, analysis methods and prediction methods are the same.
[0143] Example 4 A prediction system for lymphoma immunophenotyping based on flow cytometry
[0144] This embodiment provides a prediction system for lymphoma immunophenotyping based on flow cytometry, which is basically the same as the prediction system provided in Example 2, except that: the detection module includes a preparation process of the cell fluid to be tested, after adding the OPtiLyse C reagent, incubating at room temperature (18°C to 25°C) in the dark for 3 minutes; after adding 2 mL of room temperature FACSLysing solution (1×), incubating in a 37°C water bath in the dark for 3 minutes, and the remaining steps and parameters, analysis methods and prediction methods are the same.
[0145] Typical Cases
[0146] Case 1: Target object 1 is tested according to the prediction system for lymphoma immunophenotyping based on flow cytometry provided in Example 2 of the present invention. The test module performs on-machine testing and the data analysis module performs analysis. The specific analysis content is as follows:
[0147] S1. Establishment of CD45-SS map
[0148] In the target sample 1, the cells to be tested are cut off from the adhesion bodies and cell fragments, and the CD45-SS detection diagram is as follows Figure 8 As shown. Figure 8 a) is the detection picture after the adhesion of the cells to be tested is cut off; Figure 8 b) is a detection picture after cutting off adhesion bodies and cell fragments; Figure 8 c) is the detection diagram of CD45-SS of cells to be tested.
[0149] S2. Analysis of B cells within the lymphocyte gate
[0150] In the sample of target object 1, the development of B cells and the proportion of lymphocytes are detected as follows Fig. 9 shown; Fig. 9 a) is a detection diagram of CD19 positive cells to be tested; Fig. 9 b) is a detection diagram of CD10 and CD20 developmental patterns of B progenitor cells and B cells; Fig. 9 c) Detection chart of the ratio of B cells to lymphocytes.
[0151] In the sample of target object 1, the detection chart of B cell immune phenotype (expression of CD5, CD10 or cell membrane light chain Kappa and Lambda) is as follows Fig.10 As shown, Fig.10 a) is a detection diagram of the expression of CD5 in B cells to be tested; Fig.10 b) is the expression of CD10 on the B cells to be tested; Fig.10 c) is a detection diagram of the expression of Kappa and Lambda light chains on the cell membrane of the B cells to be tested.
[0152] S3. Analysis of T cells and NK cells within the lymphocyte gate
[0153] In the sample of target object 1, the ratio of T cells and NK cells to lymphocytes is shown in the following figure: Fig.11 shown; Fig.11 a) is a CD3 positive cell detection diagram; Fig.11 b) is a detection diagram of the proportion of CD3 positive cells to lymphocytes; Fig.11 c) Detection chart of CD3-positive T cells, NKT cells and the proportion of NK cells in lymphocytes.
[0154] In the sample of target object 1, the development detection diagram of CD4 and CD8 in T cells is as follows Fig.12 shown; Fig.12 a) is a detection diagram of T cell CD4 expression; Fig.12 b) is a detection diagram of T cell CD8 expression; Fig.12 c) is a detection diagram of CD4+CD8+T cells, CD4+CD8-T cells, CD4-CD8+T cells and the proportion of CD4-CD8+T cells to T cells.
[0155] In the sample of target object 1, the development detection diagram of CD7, CD5 and CD2 in T cells and NK cells is as follows Fig.13 shown; Fig.13 a) is a detection diagram of CD7 expression in T cells and NK cells; Fig.13 b) is the detection diagram of CD5 expression of T cells and NK cells; Fig.13 c) is the detection diagram of CD2 expression of T cells and NK cells.
[0156] S4. Analysis of the expression of different lymphocyte cross-lineage antigens in lymphocytes
[0157] Observe whether different lymphocytes in the target object 1 sample express across different lines. Fig.14 shown; Fig.14 a) is the lymphocyte CD3 / CD19 detection diagram; Fig.14 b) is the detection diagram of lymphocyte CD3 / CD10 expression; Fig.14 c) is the detection diagram of lymphocyte CD7 / CD10 expression; Fig.14 d) is the detection diagram of lymphocyte CD56 / CD19 expression.
[0158] S5. Based on the above analysis results of the expression of B cells, T cells, NK cells and cross-lineage antigens in the lymphocyte gate, predict whether it is a mixed lymphoma of any two of the three types of cells: B cells, T cells or NK cells.
[0159] After analysis, the proportion of abnormal B cells in the target subject 1 sample to lymphocytes was about 97.40% (increased proportion of lymphocytes), Kappa and Lambda were not expressed, with increased expression of CD5 and decreased expression of CD20; T cells and NK cells were not abnormal. The prediction result is: suspected B-cell lymphoma.
[0160] The target subject was further clinically screened and diagnosed with B-cell lymphoma.
[0161] Case 2: Target object 2 was tested according to the prediction system for lymphoma immunophenotyping based on flow cytometry provided in Example 2 of the present invention, and the detection module was used for on-machine detection, and the data analysis module was used for analysis. After analysis, the proportion of abnormal T cells in the sample of target object 2 was about 93.61% of lymphocytes (the proportion of lymphocytes was significantly increased), the CD4:CD8 ratio was less than 10:1, and the expression of CD2, CD5 and CD7 was weakened; B cells and NK cells were not abnormal. The prediction result is: suspected T-cell lymphoma. The target object was further clinically screened and diagnosed with B-cell lymphoma.
[0162] In this case, only the detection graphs with abnormal expression are provided, and the detection graphs without obvious abnormalities are not repeated. Among them, the detection graph of the proportion of T cells and NK cells in lymphocytes in the target object 2 sample is as follows Fig.15 shown; Fig.15 a) is a CD3 positive cell detection diagram; Fig.15 b) is a detection diagram of the proportion of CD3 positive cells to lymphocytes; Fig.15 c) CD3 positive T cells, NKT cells, and NK cell to lymphocyte ratio detection chart. In the target object 2 sample, the T cell CD4 and CD8 development detection chart is as follows Fig.16 shown; Fig.16 a) is a detection diagram of T cell CD4 expression; Fig.16 b) is a detection diagram of T cell CD8 expression; Fig.16 c) is a detection chart of the proportion of T cells CD4+CD8+T cells, CD4+CD8-T cells, CD4-CD8+T cells, and CD4-CD8+T cells to T cells. In the sample of target object 2, the development detection chart of T cells and NK cells CD7, CD5, and CD2 is as follows Fig.17 shown; Fig.17 a) is a detection diagram of CD7 expression in T cells and NK cells; Fig.17 b) is the detection diagram of CD5 expression of T cells and NK cells; Fig.17 c) is the detection diagram of CD2 expression of T cells and NK cells.
[0163] Case 3: Target object 3 was tested according to the prediction system for lymphoma immunophenotyping based on flow cytometry provided in Example 2 of the present invention, and the detection module was used for on-machine detection, and the data analysis module was used for analysis. After analysis, the target object 3 sample had a high proportion of abnormal B cells, and the Kappa: Lambda ratio of the B cell membrane was greater than 3; accompanied by abnormal T cells, the CD3 antigen expression in the T cells was absent, and the CD2 antigen expression was weakened; NK cells were not abnormal. The prediction result is: suspected B cell / T cell mixed lymphoma. After further clinical screening, the target object was diagnosed with B cell lymphoma accompanied by T cell lymphoma.
[0164] In this case, only the test graphs with abnormal expression are provided, and the test graphs without obvious abnormality are not repeated. Among them, the test graphs of B cell development and lymphocyte proportion in target object 3 sample are shown in the following figure: Fig.18 shown; Fig.18 a) is a detection diagram of CD19 positive cells to be tested; Fig.18 b) is a detection diagram of CD10 and CD20 developmental patterns of B progenitor cells and B cells; Fig.18 c) Detection chart of the proportion of B cells to lymphocytes. In the sample of target object 3, the detection chart of B cell immune phenotype and the development of CD7, CD5 and CD2 of T cells and NK cells is as follows Fig.19 Shown in Fig.19 a) is a detection diagram of the expression of CD5 in B cells to be tested; Fig.19 b) is the expression of CD10 on the B cells to be tested; Fig.19 c) is a detection diagram of the expression of Kappa and Lambda light chains on the cell membrane of the B cells to be tested; Fig.19 d) is the detection diagram of CD7 expression in T cells and NK cells; Fig.19 e) is a detection diagram of CD5 expression in T cells and NK cells; Fig.19 f) is the detection diagram of CD2 expression of T cells and NK cells.
[0165] In the target object 3 sample, the ratio of T cells and NK cells to lymphocytes is shown in the following figure: Fig. 20 shown; Fig. 20 a) is a CD3 positive cell detection diagram; Fig. 20 b) is a detection diagram of the proportion of CD3 positive cells to lymphocytes; Fig. 20 c) Detection chart of CD3-positive T cells, NKT cells and the proportion of NK cells in lymphocytes.
[0166] Comparative Example 1
[0167] This comparative example provides a prediction method for lymphoma immunophenotyping using traditional flow cytometry samples + traditional two-tube analysis. The specific process is as follows:
[0168] 1. The detection module includes the preparation of the cell fluid to be tested and the on-machine detection. The specific operation process is as follows:
[0169] (1) Take 2 mL of human bone marrow sample and immediately place it in a heparin anticoagulant tube and mix well to prevent the sample from coagulating to obtain the test sample;
[0170] (2) Cell counting: Take 10 μL of the above sample and add 150 μL of PBS, mix well, and count the number of cells per microliter. According to the test results, the number of cells in each tube is controlled at 1×10 6 ~2×10 6 indivual;
[0171] (3) Add the antibody composition listed in Table 2 below and 100 μL of the cell solution adjusted for cell concentration in step (2) to each test tube, gently rotate the test tube, and incubate at room temperature (18°C to 25°C) for 15 min under the conditions specified in the antibody data sheet.
[0172] Table 2
[0173] Tube 1 Antibody-Fluorescein / Amount Tube 2 Antibody-Fluorescein / Dosage Anti-CD8 antibody-FITC (5 μL) Anti-Kappa antibody-FITC (2.5 μL) Anti-CD4 antibody--FE (5μL) Anti-Lambda antibody-PE (2.5 μL) Anti-CD3 antibody-ECD (5 μL) Anti-CD34 antibody-ECD (5 μL) <![CDATA[Anti-CD56 antibody-PerCP-Cy TM 5.5 (2.5 μL)]]> <![CDATA[Anti-CD19 antibody-PerCP-Cy TM 5.5 (2.5 μL)]]> Anti-CD7 antibody-PE-CY7 (2.5 μL) Anti-CD10 antibody-PE-CY7 (2.5 μL) Anti-CD5 antibody-APC (1.25 μL) Anti-CD5 antibody-APC (1.25 μL) Anti-CD2 Antibody-Pacific Blue (1.25μL) Anti-CD20 antibody-Briliant Violet 421 (1.25μL) <![CDATA[Anti-CD45 antibody - Spark Violet TM 538 (1.25 μL)]]> <![CDATA[Anti-CD45 antibody - Spark Violet TM 538 (1.25 μL)]]>
[0174] (4) Add 0.5 mL of OPtiLyse C reagent and vortex immediately, incubate at room temperature (18°C to 25°C) in the dark for 10 min; add 0.5 mL of PBS and stir, incubate at room temperature (18°C to 25°C) in the dark for at least 5 min;
[0175] (5) Centrifuge at 300 g for 5 min at room temperature;
[0176] (6) Discard the supernatant and leave about 50uL of liquid in the test tube to avoid damaging the cell pellet;
[0177] (7) Mix at low speed, resuspend the cells in PBS buffer containing 1% calf serum, add 2 mL of PBS containing 0.1% sodium azide to each tube to wash the cells, mix at low speed, and centrifuge at 300 g for 5 min at room temperature;
[0178] (8) Aspirate the supernatant, leaving about 50uL of liquid in the test tube to avoid damaging the cell cluster; mix at low speed, resuspend the cells in PBS buffer containing 1% calf serum, add 500uL PBS to each tube, and mix at low speed.
[0179] (10) Cover the processed sample tube and obtain the cell fluid to be tested. Store the cell fluid in the dark at 2-8°C until it is ready for testing. It is best to analyze the sample within 24 hours after staining. Mix the suspension thoroughly before loading to prevent cell aggregation.
[0180] (11) Turn on the Navios flow cytometer and preheat the machine for more than 20 minutes. Test the internal quality control product to ensure that all test values are within the control range. Load the AL-PANEL sample and collect data. According to the set instrument conditions, obtain 300,000 cells per tube.
[0181] 2. Data analysis: The specific contents are as follows:
[0182] 1. Analyze the expression of relevant antigens in tube 1
[0183] (1) FS INT and FS PEAK were used to cut off adhesions, CD45-FS was used to cut off cell fragments, and CD45-SS was used to roughly divide the cells to be tested into five gates: granulocytes, monocytes, lymphocytes, CD45dim, and CD45neg.
[0184] (2) Preliminary observation of CD3 / CD4 / CD8 / CD56 expression of CD3+ T lymphocytes and NK lymphocytes. For example, the ratio of CD4 to CD8 in T cells is observed. The ratio of CD4 to CD8 in normal T cells is 0.5-3.0. If the ratio of CD4 to CD8 in the T cells to be tested does not fall within the range of (0.5, 3.0), it is judged as suspected abnormality.
[0185] It is important to observe the CD4 / CD8 ratio. If the CD4 / CD8 ratio is unbalanced, greater than 10:1 or less than 1:10, a large number of CD8+T cells can be seen during viral infection accompanied by downregulation of CD7 expression, so pay attention to identification;
[0186] (3) Observe the expression of CD5 / CD7 / CD2 in CD3+T lymphocytes and NK lymphocytes through CD3 / CD5 / CD7 / CD2.
[0187] Among the abnormal pan-T cell antigen expression, abnormal expression of CD3, CD5, and CD7 is more common, while abnormal expression of CD2 is relatively rare. Antigen expression is often reduced or absent, and a small number of patients may show upregulated antigen expression;
[0188] (4) The lymphocyte gate was used to observe the ratio of T lymphocytes / NK lymphocytes to lymphocytes, the ratio of different T lymphocyte subsets CD4+CD8+ / CD4-CD8- / CD4-CD8+ / CD4+CD8-, and the ratio of CD3+CD4+T lymphocytes / CD3+CD8+T lymphocytes.
[0189] Normal T cells account for 50-70%, NKT cells account for 20-30%, and NK cells account for 10-40%. T-NHL and NK-NHL will have an increased proportion. Through the logical lymph node gate, observe the CD3 / CD56 graph, where CD3+ is T cells, CD3+CD56+ is NKT cellsNKT, and CD3-CD56+ is NK cells, showing the proportion of cells in the gate.
[0190] Among them, the cells to be tested were cut off from adhesion bodies and cell fragments, and the CD45-SS detection diagram was as follows Fig.21 As shown, Fig.21 a) is the detection picture after the adhesion of the cells to be tested is cut off; Fig.21 b) is a detection picture after cutting off adhesion bodies and cell fragments; Fig.21 c) is the CD45-SS detection diagram of the cells to be tested. The detection diagram of the proportion of T cells and NK cells in lymphocytes is as follows Fig. 22 As shown, Fig. 22 a) is a CD3 positive cell detection diagram; Fig. 22 b) is a detection diagram of the proportion of CD3 positive cells to lymphocytes; Fig. 22 c) CD3 positive T cells, NKT cells, and NK cell to lymphocyte ratio detection chart. T cell CD4 and CD8 development detection chart as shown Fig.23 As shown, Fig.23 a) is a detection diagram of T cell CD4 expression; Fig.23 b) is a detection diagram of T cell CD8 expression; Fig.23 c) is a detection chart of the proportion of CD4+CD8+T cells, CD4+CD8-T cells, CD4-CD8+T cells and CD4-CD8+T cells in T cells. The detection chart of CD7, CD5 and CD2 development of T cells and NK cells is as follows Fig.24 As shown, Fig.24 a) is a detection diagram of CD7 expression in T cells and NK cells; Fig.24 b) is the detection diagram of CD5 expression of T cells and NK cells; Fig.24 c) is the detection diagram of CD2 expression of T cells and NK cells.
[0191] 2. Analysis of related antigen expression in tube 2
[0192] (1) FS INT and FS PEAK were used to cut off adhesions, CD45-FS was used to cut off cell fragments, and CD45-SS was used to roughly divide the cells to be tested into five gates: granulocytes, monocytes, lymphocytes, CD45dim, and CD45neg.
[0193] (2) Circle the CD19+ population using the CD19+SS graph, circle CD10-CD20+ mature B cells and CD10+CD20-B progenitor cells in the CD19+ gate, and observe the proportion of B lymphocytes in the lymphocyte gate CD19+CD20+. B progenitor cells are the precursor cells of mature B lymphocytes, that is, B progenitor cells develop into mature B lymphocytes in the later stage.
[0194] (3) The overall Kappa / Lambda and lymphocyte gate Kappa / Lambda were used to observe the expression of B lymphocyte cell membrane light chains. The CD19-FS gate was set to observe the proportion of B lymphocytes in lymphocytes.
[0195] Normal cells have polyclonal expression of membrane light chains, with a Kappa / Lambda ratio of approximately 1 / 3-3, and the cell volume is consistent with other lymphocytes. Abnormal B cells have monoclonal expression of membrane light chains, with a Kappa / Lambda ratio not within the range of 1 / 3-3, and the cell volume may be larger than other lymphocytes.
[0196] (4) Using the CD19 / CD10 / CD20 / CD5 antibody combination, we observed the expression and development of CD10 / CD5 / CD20 on B lymphocytes.
[0197] Normal mature B lymphocyte phenotype is CD19 + CD20 + CD10 - CD5 - , which may be accompanied by a small amount of CD5+ expression. Abnormal B cells will have abnormal expression of CD10 and CD5 and increased or decreased expression of CD20 / CD19. The normal B progenitor cell immunophenotype is CD19 + CD10 + CD20 - .
[0198] If the Kappa:Lambda ratio of B cells is <0.3 or the Kappa:Lambda ratio of B cells is >3.0, CD5+10-NH-B, CD5+CD10+NHL-B, CD5-CD10-NHL-B and CD5-CD10+NHL-B can be preliminarily screened according to the expression of CD5 and CD10; the prediction results can be output as: suspected CD5+CD10-type B cell lymphoma, CD5-CD10-type B cell lymphoma, CD5+CD10+ type B cell lymphoma or CD5-CD10+ type B cell lymphoma.
[0199] The development of B cells and the proportion of lymphocytes in the cells to be tested are shown in the figure below. Fig.25As shown, Fig.25 a) is a detection diagram of CD19 positive cells to be tested; Fig.25 b) is a detection diagram of CD10 and CD20 developmental patterns of B progenitor cells and B cells; Fig.25 c) is the detection diagram of the proportion of B cells to lymphocytes. The detection diagram of B cell immune phenotype (expression of CD5, CD20, CD10 and cell membrane light chains Kappa and Lambda) in the cells to be tested is as follows Fig.26 As shown, Fig.26 a) is a detection diagram of the expression of CD5 in B cells to be tested; Fig.26 b) is a detection diagram of the expression of CD20 on B cells; Fig.26 c) is the expression of CD10 on B cells; Fig.26 d) is the detection diagram of the expression of B cell membrane light chains Kappa and Lambda.
[0200] Compared with the prediction system provided in Example 2, the prediction system provided in this comparative example has the following limitations:
[0201] (1) Analysis tube 1 can only observe T lymphocytes and NK lymphocytes, but not B lymphocytes, and analysis tube 2 can only observe B lymphocytes, but not T lymphocytes and NK lymphocytes. Therefore, when predicting lymphoma immunophenotyping, the single-tube solution of this comparative example can only observe one or one type of disease.
[0202] (2) Traditional two-tube analysis method: two tubes are repeatedly gated for antibody CD45 and cross-antigen antibodies abnormally expressed by B and T lineages, such as CD5 / CD10.
[0203] (3) Only the expression of CD5 / CD10 / CD20 / CD19 in the CD34-positive population can be observed, and it cannot be combined with the expression of T-lineage-related antibodies CD2 / CD7 / CD56.
[0204] Effect example
[0205] In order to investigate the practicability of the flow sample preparation method and data analysis method in the prediction system provided in Example 2, a methodological investigation was conducted by comparing them with the traditional flow sample preparation method and data analysis method provided in Comparative Example 1.
[0206] 1. Accuracy experiment: In order to determine the accuracy of the results and evaluate the size of the system error, the following experiment was conducted: bone marrow specimens from healthy people were selected and measured using two different processes. The experimental results were recorded and the differences were calculated. The specific results are shown in Table 3 below.
[0207] Table 3
[0208] Process / Cell Ratio Example 2 Comparative Example 1 Difference Lymphocyte percentage 14.73 15.22 -0.49 T subgroup % 71.98 70.79 1.19 B subgroup % 12.82 12.18 -1.36 NK subpopulation percentage 8.52 8.45 0.07
[0209] 2. Precision test: In order to evaluate the magnitude of random errors in the measurement results, the following experiments were performed: (1) Intra-batch repeat tests and inter-batch repeat tests, as follows:
[0210] (1) Intra-batch repeat test: Anticoagulated bone marrow samples from healthy subjects were used for continuous sampling and testing 10 times in the same time period using two different processes. Details are shown in Tables 4-1 and 4-2 below.
[0211] Table 4-1
[0212]
[0213] Table 4-2
[0214]
[0215] (2) Repeated test between batches: Use anticoagulated blood samples from bone marrow of healthy people and test them once using two different processes at the same time every day for 10 consecutive days. Details are shown in Table 5-1 and Table 5-2 below.
[0216] Table 5-1
[0217]
[0218] Table 5-2
[0219]
[0220] 3. Stability test: After the specimen is prepared, abnormalities are detected every 8 hours. The analysis results at different storage times within 24 hours can be examined, as shown in Table 6.
[0221] Table 6
[0222]
[0223] Through methodological investigation, it can be seen that compared with the traditional flow sample preparation process and the traditional two-tube analysis method, the improved flow sample preparation process and single-tube analysis method provided by the present invention have better precision and stability and good accuracy. This prediction method can greatly shorten the experimental time, save antibodies, and improve work efficiency.
[0224] After further investigation, the repeatability and stability of the improved flow sample preparation process and single-tube analysis method provided in Examples 3 and 4 of the present invention also achieved similar results to the method provided in Example 2, and the present invention will not repeat them.
[0225] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modification, equivalent substitution or improvement made within the spirit and principle of the present invention should be included in the protection scope of the present invention.
Claims
1. An antibody composition for lymphoma immunophenotyping based on flow cytometry, characterized in that: The antibody composition includes anti-CD8 antibody, anti-CD4 antibody, anti-CD10 antibody, anti-CD3 antibody, anti-CD56 antibody, anti-CD7 antibody, anti-CD5 antibody, anti-CD34 antibody, anti-CD10 antibody, anti-CD19 antibody, anti-CD2 antibody, anti-CD20 antibody, anti-CD45 antibody, anti-Kappa antibody and anti-Lambda antibody; The antibody composition is mixed in the same flow tube during detection.
2. The antibody composition for lymphoma immunophenotyping based on flow cytometry according to claim 1, characterized in that: The antibody is labeled with different fluorescent markers; the fluorescent marker is selected from FITC, PE, ECD, PE-CY7, PerCP-Cy TM 5.5, APC, APC Alexa Fluor 700, Pacific Blue, Brilliant Violet 421, Spark Violet TM 538, APC-Cy7 TM 7.
3. The antibody composition for lymphoma immunophenotyping based on flow cytometry according to claim 2, characterized in that: The labeling coordination relationship between the fluorescent label and the antibody is: anti-Kappa antibody and anti-CD8 antibody are labeled with FTIC, anti-Lambda antibody and anti-CD4 antibody are labeled with PE, anti-CD3 antibody is labeled with ECD, and anti-CD56 antibody is labeled with PerCP-Cy TM 5.5, anti-CD7 antibody labeled with PE-Cy7, anti-CD5 antibody and anti-CD34 antibody labeled with APC, anti-CD10 antibody labeled with APC Alexa Fluor700, anti-CD19 antibody labeled with APC-Cy7 TM 7. Anti-CD2 antibody labeled Pacific Blue, anti-CD20 antibody labeled BriliantViolet 421, anti-CD45 antibody labeled Spark Violet TM 538.
4. A prediction system for lymphoma immunophenotyping based on flow cytometry, characterized in that: The prediction system includes a data detection module and a data analysis module; Wherein, the detection module is used to detect the antigen expression of the cell fluid to be tested by flow cytometry, wherein the cell fluid to be tested comprises a sample to be tested, a hemolysin composition and an antibody composition for lymphoma immunophenotyping based on flow cytometry according to any one of claims 1 to 3; The data analysis module is used to analyze the detection results of the detection module and predict lymphoma immunophenotyping according to predetermined judgment criteria.
5. The prediction system for lymphoma immunophenotyping based on flow cytometry according to claim 4, characterized in that: The lymphoma includes B-cell lymphoma, T-cell lymphoma or NK-cell lymphoma, and mixed lymphoma of any two of the three types of cells: B cells, T cells or NK cells.
6. The prediction system for lymphoma immunophenotyping based on flow cytometry according to claim 4, characterized in that: In the detection module, the hemolysin composition includes OPtiLyse C reagent and FACS Lysing solution; The preparation process of the cell fluid to be tested includes: mixing the antibody composition for lymphoma immunophenotyping based on flow cytometry with the sample to be tested, adding OPtiLyse C reagent, incubating at 18-25° C. in the dark for 2-3 minutes, adding FACSLysing solution, and incubating at 36-38° C. in the dark for 2-3 minutes to obtain the cell fluid to be tested; The sample to be tested includes a peripheral blood sample or a bone marrow sample.
7. The prediction system for lymphoma immunophenotyping based on flow cytometry according to claim 4, characterized in that: The data analysis module executes the following process: obtaining the result data of the data detection module, cutting off the adhesion and cell debris data, setting a gate with CD45-SS, and dividing the cell population into a granulocyte area, a monocyte area, a lymphocyte area, a CD45 weakly positive area and a CD45 negative area according to the expression of CD45, and after circling the target cell population, analyzing the expression of B cells, T cells, NK cells and different lymphocyte cross-lineage antigens in the lymphocyte gate.
8. The prediction system for lymphoma immunophenotyping based on flow cytometry according to claim 7, characterized in that: The analysis of the expression of B cells, T cells, NK cells and different lymphocyte cross-lineage antigens within the lymphocyte gate specifically includes the following contents: (1) Analysis of B cells within the lymphocyte gate, including gating B cells using CD19-SS; Observe the CD45 weak positive area or CD45 negative area, and combine the CD34 expression and CD20-CD10 pattern expression to predict the probability of B lymphoblastic leukemia; and / or Observe the development trend of B progenitor cells and mature B cells, and predict the probability of B cell lymphoma based on the proportion of mature B cells in lymphocytes; and / or Observe the expression of Kappa-Lambda, a light chain on the membrane of mature B cells, and predict the probability of B-cell lymphoma; (2) Analysis of T cells and NK cells within the lymphocyte gate, including gating T cells and NK cells using CD3-SS; Observe the CD45 weakly positive area or CD45 negative area, and combine it with the CD34 expression to predict the probability of T lymphoblastic leukemia; and / or Observe the CD4 / CD8 ratio in T cells within the logical lymphatic gate, whether the pan-T cell antigen expression is abnormal, or whether there is abnormal increase in the expression of a single antigen in T cells, and predict the probability of T cell lymphoma; and / or Observe the NK cells in the lymphocyte gate, including circling NK cells or T cells with CD3-CD19-, observe the ratio of NK cells to lymphocytes in the logical lymphocyte gate, and predict the probability of NK cell lymphoma by combining the abnormal expression of antigens including CD56, CD7, CD2 or CD5; (3) Based on the above analysis results of the expression of B cells, T cells, NK cells and cross-lineage antigens in the lymphocyte gate, the probability of mixed lymphoma of any two of the three types of cells, B cells, T cells or NK cells, is predicted.
9. The prediction system for lymphoma immunophenotyping based on flow cytometry according to claim 8, characterized in that: The B cells in the lymphocyte gate are analyzed, and when the ratio of Kappa / Lambda of the cell membrane light chain of the mature B cells does not fall within the range of 0.3 to 3.0 or Kappa / Lambda is not expressed, the cells are determined to be abnormal mature B cells, and the probability of B cell lymphoma is predicted based on the ratio of the abnormal mature B cells; and / or further based on the expression of CD5 and CD10, the prediction result is output as any one of suspected CD5+CD10- B cell lymphoma, CD5-CD10- B cell lymphoma, CD5+CD10+ B cell lymphoma or CD5-CD10+ B cell lymphoma; and / or The analysis of T cells and NK cells in the lymphocyte gate predicts the probability of T cell lymphoma when the proportion of T cells in the logical lymphocyte gate to lymphocytes is greater than 70% or when the CD4 / CD8 ratio of T cells in the logical lymphocyte gate does not fall within the range of 0.5 to 3.0; and / or The analysis of T cells and NK cells in the lymphocyte gate, CD3-CD19- gate, CD4+ accompanied by abnormal expression of CD56, CD5, CD7 or CD2 antigens, determines them as abnormal T cells, and predicts the probability of T cell lymphoma based on the proportion of the abnormal T cells; and / or The T cells and NK cells in the lymphocyte gate are analyzed. When the proportion of NK cells in the logical lymphocyte gate to lymphocytes is greater than 40%, or CD4- in the CD3-CD19- gate is accompanied by abnormal expression of CD56, CD5, CD7 or CD2 antigens, the probability of T cell lymphoma or NK cell lymphoma is predicted.
10. The prediction system for lymphoma immunophenotyping based on flow cytometry according to claim 7, characterized in that: The analysis of the expression of cross-lineage antigens of different lymphocytes by lymphocytes is performed by analyzing the expression of specific antibody pairs or antibodies within the logical lymphatic gate, observing the cross-lineage expression between different lymphocytes, and outputting the prediction results of targeted follow-up screening; The specific antibody pairs or antibody combinations include (CD5+CD34)-CD10, CD3-CD10, CD7-CD10 or CD3-CD19 or CD19-CD7 or CD19-CD56.
Citation Information
Patent Citations
Molecular marker and application thereof in detection of vascular immunoblastic T cell lymphoma
CN113484520A
Antibody composition and method for detecting minimal residue of acute B lymphocytic leukemia
CN113933511A
Reagent composition for B-ALL / LBL immunological typing and application thereof
CN114460311A
Antibody combination for replacing lateral scattering light signal in mass spectrum flow type blood tumor immunotyping and application thereof
CN114720358A
